Intracellular IL-24 ameliorates lipid metabolic disorders in metabolic dysfunction-associated steatohepatitis by restoring the autophagy-lysosome pathway
Cellular and Molecular Life Sciences · 2025
DOI: 10.1007/s00018-025-05940-1 ↗At a glance
Journal article in Cellular and Molecular Life Sciences, 2025. Written by Jiawei Cui and 11 co-authors. Institution: Department of Traditional and Western Medical Hepatology, Hebei Provincial Key Laboratory of liver fibrosis in chronic liver diseases, Hebei Medical …. Major MEDLINE topics: Autophagy, Interleukins, Lysosomes, Fatty Liver. Cited 6 times so far (Crossref); 36 references. The full text is freely available (open access, CC BY 4.0). Funded by: Hebei Provincial Department of Education graduate Innovation Funding Program, National Natural Science Foundation of China.
Abstract (original language)
Background
Metabolic dysfunction-associated steatohepatitis (MASH) is associated with impaired hepatic autophagy, but its key regulators remain unclear. This study delineates IL-24 as a regulator of autophagy in MASH.
Methods
IL-24 was identified via bioinformatics in patient datasets and validated in metabolic dysfunction-associated steatotic liver disease (MASLD) patient sera. A high-fat high-fructose diet (HFFD) induced MASH in mice, with IL-24 overexpression via adeno-associated virus. Functional assessments were performed both in vivo and in primary hepatocytes using immunohistochemistry, Western blot, immunofluorescence, dual-fluorescence autophagic flux tracking, and multi-omics analyses.
Results
MASLD patients and animal models showed significantly lower IL-24 expression, with levels inversely related to disease severity. IL-24 intervention improved liver steatosis, inflammation, fibrosis, and insulin resistance in MASH mice. Mechanistically, IL-24 mediates hepatocyte autophagy and alleviates lipid accumulation through the IL-22R1/IL-20R2 receptor complex. It activated AMP-activated protein kinase (AMPK), suppressed mechanistic target of rapamycin (mTOR), enhanced transcription factor EB (TFEB) nuclear translocation (as evidenced by reduced microtubule-associated protein 1 A/1B-light chain 3-II/sequestosome 1), restored autophagy-lysosome function, and increased lipid degradation. Multi-omics analysis indicated increased fatty acid oxidation and decreased glucose metabolism. Notably, KEGG enrichment analysis revealed significant association of differential metabolites with autophagy-related pathways, corroborating findings from transcriptomics and the AMPK/mTOR/TFEB regulatory axis.
Conclusion
IL-24 preferentially utilizes the IL-22R1/IL-20R2 receptor complex to modulate the AMPK/mTOR/TFEB axis, thereby inducing autophagic-lysosomal activation, regulating glucose and lipid metabolism, and ameliorating hepatic lipid accumulation in MASH. These findings highlight IL-24 as a novel therapeutic target for MASH. Graphical Abstract
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Traditional and Western Medical Hepatology, Hebei Provincial Key Laboratory of liver fibrosis in chronic liver diseases, Hebei Medical University Third Hospital, Shijiazhuang, 050051, Hebei, P.R. China.
- Department of Traditional and Western Medical Hepatology, Hebei Provincial Key Laboratory of liver fibrosis in chronic liver diseases, Hebei Medical University Third Hospital, Shijiazhuang, 050051, Hebei, P.R. China. na…
- Hebei International Joint Research Center for Liver Cancer Molecular Diagnosis, Hebei International Science and Technology Cooperation Base, Shijiazhuang, 050051, Hebei, P.R. China. nanyuemin@hebmu.edu.cn.
Funding
- Hebei Provincial Department of Education graduate Innovation Funding Program
- National Natural Science Foundation of China
Cite
APA
Cui, J., Lin, Z., Sun, M., He, Y., Mao, Y., Zhang, C., Shi, Y., Chen, Y., Li, S., Zhang, Y., Zheng, Q., & Nan, Y. (2025). Intracellular IL-24 ameliorates lipid metabolic disorders in metabolic dysfunction-associated steatohepatitis by restoring the autophagy-lysosome pathway. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-025-05940-1
Vancouver
Cui J, Lin Z, Sun M, He Y, Mao Y, Zhang C, et al. Intracellular IL-24 ameliorates lipid metabolic disorders in metabolic dysfunction-associated steatohepatitis by restoring the autophagy-lysosome pathway. Cellular and Molecular Life Sciences. 2025. doi:10.1007/s00018-025-05940-1
BibTeX
@article{Cui2025,
author = {Cui, Jiawei and Lin, Zhandong and Sun, Mengjiao and He, Yuyuan and Mao, Yaoyao and Zhang, Congyue and Shi, Yue and Chen, Yukai and Li, Shaoya and Zhang, Ying and Zheng, Qianqian and Nan, Yuemin},
title = {Intracellular IL-24 ameliorates lipid metabolic disorders in metabolic dysfunction-associated steatohepatitis by restoring the autophagy-lysosome pathway},
journal = {Cellular and Molecular Life Sciences},
year = {2025},
doi = {10.1007/s00018-025-05940-1}
}
EUVIMED